PharmaTelevision - Deborah Rathjen explains why these are exciting times for Bionomics

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Deborah Rathjen explains why these are exciting times for Bionomics

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Dr Deborah Rathjen, CEO and MD of Bionomics Ltd.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Clinical trials at Bionomics

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at AusBiotech in Melbourne. On this show I have Deborah Rathjen , who is CEO of a company called Bionomics , but also is Chairman of AusBiotech, welcome to the show.

Deborah Rathjen :

Thanks Fintan.

Fintan Walton:

Deborah Rathjen , I've said you are CEO of Bionomics it's an ASX listed company, tell us all about Bionomics , what sort of company are you?

Deborah Rathjen :

We are an ASX listed company, our current market capitalization is of the order of 90 million. We have four clinical trials ongoing in two different therapeutic areas all of these trials will report in the first half of next year, so it's a very exciting time, a very key inflection point for the company in terms of value creation and the execution of our licensing strategy around both of that two key assets.

Fintan Walton:

So tell me a little bit more about these four clinical trials?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Deborah Rathjen

Chief Executive Officer

Deborah Rathjen BSc (Hons), PhD, MAICD is currently CEO and Managing Director of Bionomics Limited. A seasoned biotech executive for almost 20 years, Dr Deborah Rathjen joined Bionomics in June 2000 from Peptech, where she was general manager of business development and licensing. Dr Rathjen was a co-inventor of Peptech's TNF technology and leader of the company's successful defence of its key TNF patents against a legal challenge by BASF, providing Peptech with a strong commercial basis for licensing negotiations with BASF, Centocor and other companies with anti-TNF products. Dr Deborah Rathjen has significant experience in research, business development and licensing. Dr Deborah Rathjen is Chairperson of the AusBiotech Board, and is a member of the Higher Educatuion Council (SA Government). In 2004 Dr Deborah Rathjen was awarded the AusBiotech President's Medal for her significant contribution to the Australian biotechnology industry, in 2006 she received a Distinguished Alumni Award from Flinders University, in 2009 the BioSingapore Asia Pacific Woman Entrepreneur of the Year, and in 2010 Bio Innovation SA Industry Leader Award.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Bionomics Limited

Bionomics Limited (ASX: BNO) is a leading international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. BNC105, which is undergoing clinical development for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. A clinical program is also underway for the treatment of anxiety disorders based on BNC210 which exhibits strong anxiolytic activity without side effects in preclinical models. Both compounds offer blockbuster potential if successfully developed. Bionomics 's discovery and development activities are driven by its three technology platforms: Angene, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels). MultiCore is Bionomics ' sproprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX is a set of novel technologies for the identification of drugs targeting on channels for diseases of the central nervous system.